4.0 Article

A Primary Care Focus on the Diagnosis and Treatment of Major Depressive Disorder in Adults

期刊

JOURNAL OF PSYCHIATRIC PRACTICE
卷 17, 期 5, 页码 340-350

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.pra.0000405364.90043.bd

关键词

major depressive disorder; antidepressant; symptom remission; treatment selection; patient adherence; cost; tolerability; non-pharmacologic treatment

资金

  1. AstraZeneca
  2. Pfizer, Inc.

向作者/读者索取更多资源

Major depressive disorder (MDD), a highly prevalent psychiatric condition, is encountered in 1 of every 10 to 20 patients seen in the primary care setting. While awareness of MDD has increased, timely and accurate diagnosis and adequate treatment remain formidable challenges. Treatment options for patients with MDD should be individualized according to each patient's clinical and medication history, pharmacologic tolerability profile, and personal preferences, to maximize long-term adherence. The most robust and consistently maintained positive outcomes occur in patients who are administered effective treatment with recommended antidepressant pharmacotherapy, psychotherapy, or a combination of these treatment modalities. This manuscript reviews the epidemiology, biologic and clinical features, diagnosis, and treatment of patients with MDD. A focus is placed on guidelines and strategies that target the achievement of MDD symptom remission. The article also includes details on individualizing treatment selection and novel and emerging therapies. Primary care physicians must be prepared to adjust, substitute, or augment antidepressant treatments to optimize patient response and enhance the chances of achieving remission. Considerations that strongly influence long-term patient adherence, including tolerability and cost, are also reviewed. (Journal of Psychiatric Practice 2011; 17: 340-350)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据